查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1444889

雙胍類 - 市場佔有率分析、產業趨勢與統計、成長預測（2024 - 2029）

Biguanides - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年雙胍類市場規模預計為52.0億美元，預計到2029年將達到57.6億美元，在預測期內（2024-2029年）CAGR為2.07%。

雙胍類 - 市場

COVID-19大流行對雙胍類藥物市場產生了重大影響。因COVID-19 感染而住院的患者中糖尿病的盛行率以及人們認知到改善血糖控制可能會改善SARS-CoV-2 患者的預後並縮短住院時間，這些都突顯了口服抗糖尿病藥物市場的重要性。糖尿病患者的免疫系統較弱，COVID-19併發症會加重病情，免疫系統會很快變弱。糖尿病和不受控制的高血糖是 COVID-19 患者預後不良的危險因素，包括增加重症或死亡的風險。因此，COVID-19 的爆發加速了全球雙胍類市場的成長。

雙胍類藥物是一類用於治療第 2 型糖尿病的藥物。它們的作用是減少消化過程中葡萄糖的產生。二甲雙胍是目前大多數國家可用於治療糖尿病的唯一雙胍類藥物。 Glucophage（二甲雙胍）和 Glucophage XR（二甲雙胍緩釋劑）是這些藥物的知名品牌名稱。其他包括 Fortamet、Glumetza 和 Riomet。二甲雙胍也可以與其他幾種類型的糖尿病藥物（例如磺醯脲類藥物）合併使用。

由於第 2 型糖尿病與 COVID-19 大流行期間較差的臨床結果以及此類住院患者死亡風險的增加有關，因此強調血糖控制在改善預後方面的作用。二甲雙胍是治療 T2DM 高血糖的第一線選擇。二甲雙胍除了是一種重要的降血糖藥物外，還具有顯著的抗發炎作用。因此，二甲雙胍一直是治療受 COVID-19 感染的 2 型糖尿病患者的潛在候選藥物，也是 COVID-19 大流行期間出色的抗糖尿病（降血糖）藥物。

因此，由於上述因素，預計所研究的市場將在分析期間出現成長。

雙胍類市場趨勢

全球糖尿病盛行率上升

預計全球糖尿病人口在預測期內將增加 1.9% 以上。

根據國際糖尿病聯盟的數據，2021年成人糖尿病人口約為5.37億，預計到2030年這一數字將增加6.43億。肥胖被認為是導致這種疾病（主要是2型糖尿病）的主要因素之一。糖尿病患者血糖值持續升高可能導致腎臟、神經和眼部損傷等進行性併發症。 2 型糖尿病越來越普遍，並且與心血管和腎臟疾病風險增加有關。隨著生活方式的改變，二甲雙胍通常是一線藥物治療。

世界衛生組織已將二甲雙胍列入基本藥物清單：「滿足人口優先醫療保健需求的藥物」。二甲雙胍被歸類為用於治療第 2 型糖尿病的雙胍類藥物。它被規定用於患有胰島素抗性等疾病的人的標籤外使用。自從二甲雙胍引入 T2DM 治療以來，大量患者已成功使用這種全球可用的藥物進行治療，該藥物具有良好的風險效益，被 IDF 指南推薦為一線藥物。因此，二甲雙胍仍然是全世界最常使用的口服抗糖尿病藥物。二甲雙胍的長期積極使用經驗、臨床療效和安全性的有力證據、高依從率、低成本、普遍可用性和成本效益是其高市場佔有率的促成因素。

由於上述因素及其日益普遍，市場可能會繼續成長。

亞太地區在本年度雙胍類市場佔有率最高

亞太地區今年在雙胍類藥物市場中佔有最高的市場佔有率，約37.9%。

近年來，亞太地區糖尿病盛行率急劇上升。在中國和印度等發展中國家，糖尿病發生率處於歷史最高水平，這主要是由於生活方式的改變。根據國際糖尿病聯盟的數據，2021 年，IDF 東南亞地區有9,000 萬成年人患有糖尿病。預計到2045 年，這一數字將增加到1.52 億，而IDF 西太平洋地區有2.06 億成年人患有糖尿病。到 2021 年，該地區的人口預計到 2045 年將增加到 2.6 億。糖尿病與許多健康併發症有關。糖尿病患者需要全天進行多次調整以維持正常的血糖水平，例如口服抗糖尿病藥物、注射胰島素或透過監測血糖水平來攝取額外的碳水化合物。

根據印度政府衛生與家庭福利部統計，2021年，印度所有死亡病例中，60%與糖尿病、心血管疾病、癌症、慢性呼吸道疾病等非傳染性疾病有關。為控制主要慢性病，國家癌症、糖尿病、心血管疾病和腦中風防治規劃（NPCDCS）已啟動。該計劃包括醫學教育、學校健康意識以及糖尿病城市規劃。

由於肥胖率的上升、第2型糖尿病遺傳因素的增加、盛行率的增加以及上述因素，市場可能會持續成長。

雙胍類藥物行業概況

雙胍類藥物市場較為分散，武田、默克、賽諾菲、葛蘭素史克、百時美施貴寶、勃林格殷格翰等生產商遍布全球市場，且由於學名藥生產商的存在，市場競爭激烈。

額外的好處：

  • Excel 格式的市場估算 (ME) 表
  • 3 個月的分析師支持

目錄

第 1 章：簡介

  • 研究假設和市場定義
  • 研究範圍

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：市場動態

  • 市場概況
  • 市場促進因素
  • 市場限制
  • 波特五力分析
    • 供應商的議價能力
    • 消費者的議價能力
    • 新進入者的威脅
    • 替代產品和服務的威脅
    • 競爭激烈程度

第 5 章：市場區隔

  • 雙胍
  • 地理
    • 北美洲
      • 美國
      • 加拿大
      • 北美其他地區
    • 歐洲
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 英國
      • 俄羅斯
      • 歐洲其他地區
    • 亞太
      • 日本
      • 中國
      • 澳洲
      • 印度
      • 韓國
      • 馬來西亞
      • 印尼
      • 泰國
      • 菲律賓
      • 越南
      • 亞太其他地區
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 拉丁美洲其他地區
    • 中東和非洲
      • 南非
      • 沙烏地阿拉伯
      • 阿曼
      • 埃及
      • 伊朗
      • 中東和非洲其他地區

第 6 章：市場指標

  • 1 型糖尿病族群
  • 2 型糖尿病族群

第 7 章：競爭格局

  • 公司簡介
    • Teva
    • Merck
    • Takeda
    • GlaxoSmithKline
    • Sanofi
    • Boehringer Ingelheim
    • Glenmark
    • Zydus
    • Bristol-Myers Squibb
  • 市佔率分析
    • Merck
    • Takeda
    • Sanofi
    • 其他市佔率分析

第 8 章：市場機會與未來趨勢

簡介目錄
Product Code: 63836

The Biguanides Market size is estimated at USD 5.20 billion in 2024, and is expected to reach USD 5.76 billion by 2029, growing at a CAGR of 2.07% during the forecast period (2024-2029).

Biguanides - Market

The COVID-19 pandemic has had a substantial impact on the biguanides market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of the oral anti-diabetic drugs market. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the biguanides market's growth globally.

Biguanides are a class of medications used to treat type 2 diabetes. They work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for treating diabetes. Glucophage (metformin) and Glucophage XR (metformin extended release) are well-known brand names for these drugs. Others include Fortamet, Glumetza, and Riomet. Metformin is also available in combination with several other types of diabetes medications, such as sulfonylureas.

As Type 2 diabetes is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients, the role of glucose control has been emphasized to improve the prognosis. Metformin is the first-line choice for the management of hyperglycemia in T2DM. Besides being an important glucose-lowering agent, metformin also has significant anti-inflammatory. Therefore, metformin has been a potential candidate for treating patients affected by COVID-19 infection, with type 2 diabetes, as well as an excellent antidiabetic (glucose-lowering) agent during COVID-19 pandemic times.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Biguanides Market Trends

Rising diabetes prevalence globally

The global diabetes population is expected to rise by more than 1.9% over the forecast period.

According to the International Diabetes Federation, the adult diabetes population in 2021 was approximately 537 million, and this number is expected to increase by 643 million in 2030. Obesity is considered one of the major factors contributing to the disease, primarily type-2 diabetes. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Type-2 diabetes is increasingly prevalent and associated with an increased risk for cardiovascular and renal disease. Along with lifestyle changes, metformin is usually the first-line pharmacotherapy.

The World Health Organization has put metformin on the list of essential medicines: "medicines that satisfy the priority health care needs of the population". Metformin is classified as a biguanide used for the treatment of type-2 diabetes. It is prescribed for its off-label use in people with conditions such as insulin resistance. Since the introduction of metformin in T2DM therapy, a huge number of patients have been treated successfully with this globally available medication, which has a favorable risk-benefit profile recommended by IDF guidelines as a first-line drug. Hence, metformin is still the most prescribed oral antidiabetic medication worldwide. Long-term positive experience with the use of metformin, strong evidence of clinical efficacy and safety, a high adherence rate, low cost, general availability, and cost-effectiveness are the contributing factors to the high market share.

Owing to the aforementioned factors and their increasing prevalence, it is likely that the market will continue to grow.

Asia-Pacific region holds the highest market share in the Biguanides Market in the current year

The Asia-Pacific region holds the highest market share of about 37.9% in the biguanides market in the current year.

The Asia-Pacific region has witnessed an alarming increase in the prevalence of diabetes in recent years. In developing countries such as China and India, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. According to the International Diabetes Federation, 90 million adults were living with diabetes in the IDF South-East Asia Region in 2021. This figure is estimated to increase to 152 million by 2045, and the 206 million adults living with diabetes in the IDF Western Pacific Region in 2021, are estimated to increase to 260 million by 2045. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining normal blood glucose levels, such as oral anti-diabetic medication, insulin administration, or the ingestion of additional carbohydrates by monitoring their blood glucose levels.

According to the Ministry of Health and Family Welfare of the Government of India, in 2021, out of all deaths in India, 60% were related to non-communicable diseases like diabetes, cardiovascular diseases, cancer, chronic respiratory diseases, etc. To prevent and control major NCDs, the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) has been launched. This program includes medical education, health awareness in schools, and urban planning for diabetes.

Owing to the rising rate of obesity, the growing genetic factors for type-2 diabetes, the increasing prevalence, and the aforementioned factors, it is likely that the market will continue to grow.

Biguanides Industry Overview

The biguanides market is fragmented, with manufacturers like Takeda, Merck, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, etc. having a global market presence, and the market is highly competitive due to generic drug manufacturers' presence.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Biguanide
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Rest of North America
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 Spain
      • 5.2.2.3 Italy
      • 5.2.2.4 France
      • 5.2.2.5 United Kingdom
      • 5.2.2.6 Russia
      • 5.2.2.7 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 Japan
      • 5.2.3.2 China
      • 5.2.3.3 Australia
      • 5.2.3.4 India
      • 5.2.3.5 South Korea
      • 5.2.3.6 Malaysia
      • 5.2.3.7 Indonesia
      • 5.2.3.8 Thailand
      • 5.2.3.9 Philippines
      • 5.2.3.10 Vietnam
      • 5.2.3.11 Rest of Asia-Pacific
    • 5.2.4 Latin America
      • 5.2.4.1 Brazil
      • 5.2.4.2 Mexico
      • 5.2.4.3 Rest of Latin America
    • 5.2.5 Middle East and Africa
      • 5.2.5.1 South Africa
      • 5.2.5.2 Saudi Arabia
      • 5.2.5.3 Oman
      • 5.2.5.4 Egypt
      • 5.2.5.5 Iran
      • 5.2.5.6 Rest of Middle East and Africa

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Teva
    • 7.1.2 Merck
    • 7.1.3 Takeda
    • 7.1.4 GlaxoSmithKline
    • 7.1.5 Sanofi
    • 7.1.6 Boehringer Ingelheim
    • 7.1.7 Glenmark
    • 7.1.8 Zydus
    • 7.1.9 Bristol-Myers Squibb
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 Merck
    • 7.2.2 Takeda
    • 7.2.3 Sanofi
    • 7.2.4 Other Market Share Analyses

8 MARKET OPPORTUNITIES AND FUTURE TRENDS